InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2021 on May 5, 2021 at 08:00 a.m. CEST.

Our upcoming Phase III study CONCLUDE

CEO corner

Learn more about Peter Zerhouni, our CEO

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: